Alerta

Application of nordihydroguaiamic acid and derivatives thereof in preparation of products for treating inflammatory bowel disease

Absstract of: CN119587515A

The invention belongs to the field of biological medicines, and particularly relates to application of nordihydroguaiamic acid and derivatives thereof in preparation of products for treating inflammatory bowel diseases. By exogenous supplementation of nordihydroguaiamic acid (NDGA), DSS-induced mouse enteritis is remarkably relieved, survival prognosis of mice is improved, mucosal barrier dysfunction of UC mice is remarkably improved, the number of inflammatory macrophage subgroups is reduced, transcription generation of colon tissue proinflammatory factors and activated cleavage of pyroptosis-related proteins are inhibited, and the application of the NDGA is developed. Good anti-inflammatory effect and intestinal protection effect are achieved. The NDGA is further found to be capable of remarkably improving the mucosal barrier function disorder of the UC mouse, and the NDGA is prompted to have a good intestinal protection effect; the NDGA can inhibit the transcriptional generation of IL-1beta by regulating and controlling the NR4A1-Serpin1 pathway and reduce the co-localization of NR4A1 and NLRP3 in macrophages, which prompts that the NDGA can regulate and control the interaction relationship of NR4A1 and NLRP3 to inhibit inflammation.

Intestinal microorganism marker for irritable bowel syndrome, application of intestinal microorganism marker and method for constructing detection model

Absstract of: CN119560000A

The invention provides an irritable bowel syndrome intestinal microbial marker, application thereof and a method for constructing a detection model, and belongs to the technical field of medicine and biomedicine. By utilizing the irritable bowel syndrome intestinal microbial marker, the association between the marker level and IBS symptom severity, the life quality of a patient and the treatment effect can be evaluated, and personalized diet, prebiotics, probiotics or antibacterial drugs and other treatment suggestions are provided for the patient according to the specific intestinal microbial marker composition of the patient. According to the invention, the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of IBS are improved, the understanding of IBS is deepened, and the development of microbiomics in clinical application is promoted. The AUC value of the irritable bowel syndrome detection model reaches 0.9931, which shows that the classifier has good performance when distinguishing positive and negative samples.

Anti-TL1A antibody therapeutic methods

Absstract of: TW202509234A

The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

交联的V型胶原蛋白测定法

Absstract of: WO2024008796A1

The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.

Training method of inflammatory bowel disease diagnosis and prediction model based on data driving

Absstract of: CN119541878A

The invention provides a training method and system of an inflammatory bowel disease diagnosis and prediction model based on data driving, a storage medium and electronic equipment, and relates to the technical field of model training. According to the method, the BP feedforward neural network is adopted to process and analyze the standard data of each inspection index extracted from the ultrasonic diagnosis report text, so that the rehabilitation cycle of the patient with the inflammatory bowel disease is predicted. Through training and verification, the model shows high accuracy and reliability, and provides a powerful decision support tool for doctors. In addition, the dynamic adjustment and updating capability of the model ensures that the model can adapt to continuously changing clinical data in practical application, and the application value in personalized treatment planning and disease management is further enhanced.

一种抗血红蛋白的抗体及其应用

Absstract of: CN119529078A

本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的活性和灵敏度。

一种抗血红蛋白的抗体及其应用

Absstract of: CN119529077A

本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的亲和力或活性。

FECAL SAMPLE, BREATH SAMPLE COLLECTION AND ANALYSIS FOR TREATING INFLAMMATORY BOWEL DISEASE

Absstract of: US2025069692A1

The invention is related to a system for treating irritable bowel syndrome, Crohn's disease, ulcerative colitis (collectively, inflammatory bowel disease, or “IBD”) by determining a number of indicators, including genetic markers, gene expression levels, levels of certain compounds in the gut or feces, hydrogen and/or methane levels, and concentrations of particular bacteria in the gut or feces, and correlating one or more such indicators with symptoms in test subjects with IBD; and correlating diet, drugs, supplements or other therapy, with alleviation of IBD symptoms. The correlations established in the test subjects are confirmed or refuted for individuals suffering IBD, and the treatments established as reducing symptoms are supported through messaging and compliance is verified by monitoring the indicators.

METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT

Absstract of: AU2023257366A1

The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.

Difunctional fluorescent array sensor, preparation method thereof and application of difunctional fluorescent array sensor in bacterial detection and fermentative carbohydrate detection

Absstract of: CN119510374A

The invention relates to a fluorescent array sensor, in particular to a difunctional fluorescent array sensor containing a modified high-molecular polymer, a preparation method of the difunctional fluorescent array sensor and application of the difunctional fluorescent array sensor in bacterial detection and fermentation carbohydrate detection. The array sensor comprises at least two different fluorescent sensing units, each fluorescent sensing unit is a PN-coumarin dye compound formed by covalent interaction of PN and coumarin dye, PN is a nitrophenylboronic acid modified high-molecular polymer PEI, the coumarin dye is 6, 7-diphenyl-1, 3, 4-triazole-3-carboxylic acid, and the coumarin dye is a coumarin dye compound. The compound is selected from the group consisting of 2, 7-dihydroxy-2H-benzopyran-2-one ES or 4-methylesculetin MS. The compound fluorescent array sensor disclosed by the invention can simultaneously realize distinguishing detection of thirteen types of bacteria related to IBS and fourteen FODMAPs, and has the advantages of high sensitivity, short detection time, low cost, good repeatability, high accuracy, no need of professional technicians and the like.

BAZ2B作为靶点在非酒精性脂肪肝以及肝炎中的应用

Absstract of: CN119488592A

本申请涉及BAZ2B作为靶点在非酒精性脂肪肝以及肝炎中的应用。更具体的，本申请涉及用于调节BAZ2B表达或活性的药剂，如BAZ2B的下调剂；包含所述调节BAZ2B表达或活性的药剂的组合物；以及调节BAZ2B在细胞中表达水平或活性的方法，例如抑制BAZ2B的表达或活性的方法。本申请还涉及通过调节BAZ2B在细胞中表达水平或活性，从而治疗或改善肝脏疾病的方法，所述肝脏疾病例如包括与脂类代谢相关的疾病、非酒精性脂肪性肝病(nonalcoholic fatty liver disease，NAFLD)、非酒精性脂肪性肝炎(non‑alcoholic steatohepatitis，NASH)和肥胖。

METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE

Absstract of: US2025059605A1

The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.

DIETARY MACRO/MICRONUTRITIONAL COMPOSITIONS AND APPLICATIONS THEREOF

Absstract of: US2025057842A1

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN AS AN IMAGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Absstract of: WO2025038942A1

Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.

BACTERIAL BIOSENSORS FOR DIAGNOSING AND TREATING INFLAMMATION

Absstract of: WO2023201243A1

Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.

Compounds, pharmaceutical compositions and methods for treating inflammatory bowel disease

Absstract of: CN119487012A

The present disclosure provides a pharmaceutical composition, the pharmaceutical composition comprises a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; the present invention relates to a pharmaceutical composition comprising a dose unit comprising one or more of Compound (A), Compound (B), Compound (C), Compound (D), Compound (E), Compound (F), Compound (G), Compound (H), Compound (J), Compound (K), Compound (L), Compound (M), Compound (N), Compound (O), Compound (P), or Compound (Q) or a pharmaceutical composition described herein, a method of treating inflammatory bowel disease in a subject in need thereof, and a pharmaceutical composition comprising one or more of Compound (A), Compound (B), Compound (C), Compound (D), Compound (E), Compound (F), Compound (G), Compound (H), Compound (J), Compound (K), Compound (L), Compound (M), Compound (N), Compound (O), Compound (P), or Compound (Q). Or methods of modulating an inflammatory bowel disease marker in a subject in need thereof. # imgabs0 # imgabs1 #

Method for performing disease classification diagnosis on CT image of liver based on neural network

Absstract of: CN119478498A

A method for automatically judging which of three common diseases, namely hepatocellular carcinoma (HCC), intrahepatic cholangiocellular carcinoma (ICC) and fatty liver (FAT), the liver belongs to is based on a neural network introduced with r-IBS, and the method comprises the following steps: firstly, constructing a training classifier based on r-IBS, and judging which of the diseases belongs to each liver CT by using the classifier; and collecting CT images of the liver, carrying out image processing by using a snake model, inputting the images into the trained classification neural network model, and outputting a classification result of the diseases from the neural network.

Adipose-derived stem cell exosome and application thereof in treating colitis and mesentery

Absstract of: CN119454756A

The invention provides an adipose-derived stem cell exosome and application of the adipose-derived stem cell exosome in treatment of colitis and mesentery. It is verified for the first time that the adipose-derived stem cell exosome CrF-exo from crawling adipose tissue regulates the lymphatic endothelial cell function and promotes lymphatic drainage in colon and mesentery and finally relieves inflammation of the colon and mesentery, and it is found through verification that CrF-exo-miR-132-3p promotes the lymphatic endothelial cell function and CCL21 secretion through an RASA1/ERK1/2 axis; the miR-132-3p is highly expressed in CrF and inflammatory intestines of a CD patient along with increase of lymphatic vessel density; the expression of miR-132-3p in serum of a patient is also increased and is negatively correlated with an inflammation biomarker. The research result provides a new insight for the effect of the mesenteric lymphatic function in CD progress and a potential treatment method for targeting lymphatic vessels to treat CD mesenteric and intestinal lesions.

Preparation of cinnamyl aldehyde-loaded solid-liquid two-phase artificial cell and application of cinnamyl aldehyde-loaded solid-liquid two-phase artificial cell in targeted

Absstract of: CN119464306A

Provided is a cinnamyl aldehyde-loaded solid-liquid biphasic artificial cell (SL-BACs) which has a solid-phase protective film and a liquid multicore, and which is efficiently and stably produced using a microfluidic T-type chip. The SL-BACs can provide multi-aspect treatment assistance for colitis induced by salmonella typhimurium. Firstly, an aptamer in a liquid multinuclear shows accurate targeting at an infected part; secondly, the encapsulation efficiency of the SL-BACs on the cinnamyl aldehyde is relatively high, and is about 82.9 percent; thirdly, the intestinal retention time of the SL-BACs is prolonged to 15 h through the membrane structure; in addition, the SL-BACs show pH responsiveness, liquid multi-core antibiosis is controlled to be released, and the sterilization rate is 95.28%. The SL-BACs can also reduce the secretion of proinflammatory cytokines, optimize the composition of intestinal microbiota and maintain the steady state of the intestinal tract. In a word, the SL-BACs provide necessary conditions for modularizing the artificial cells into an oral system for targeted therapy.

CCDC71L在诊断及治疗放射性肠炎中的应用

Absstract of: CN119433017A

本发明公开了CCDC71L在诊断及治疗放射性肠炎中的应用，本发明提供了检测CCDC71L表达水平的试剂在制备放射性肠炎诊断的产品中的应用及CCDC71L的抑制剂在制备治疗放射性肠炎的药物中的应用，还提供了一种筛选治疗或预防放射性肠炎的候选药物的方法及一种抑制巨噬细胞中炎症因子表达水平的方法。本发明通过实验证明，CCDC71L能够实现放射性肠炎的诊断，并且发现抑制CCDC71L能够抑制巨噬细胞的浸润和极化进而抑制辐射诱导的炎症反应，本发明提供的CCDC71L标志物为放射性肠炎的诊断与治疗提供了新的思路，具有广阔的应用前景。

蛋白标志物在制备检测炎症性肠病的检测产品中的应用

Absstract of: CN119438591A

本申请提供了一种蛋白标志物在制备检测炎症性肠病的检测产品中的应用。其中，蛋白标志物选自如下任意一个或多个蛋白分子：MRPL43、ECHS1、TLN2、ENO3、NCSTN、CTSH、CKMT1、TUBA4A、DYNC1H1、PDLIM3、GLB1及PMPCA。本申请通过实验证明了上述12个蛋白的瓜氨酸水平与炎症性肠病高度关联，因而可将其中的一个或多个作为蛋白标志物来制备检测炎症性肠病的检测产品(比如检测或诊断试剂盒等)。基于上述蛋白标志物的检测产品有助于实现尽早检测和无创检测，快捷、方便、准确。

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

Absstract of: JP2025023316A

To provide variants of TNFSF15 and DCR3 associated with Crohn's disease.SOLUTION: Described herein are a method and a composition related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides a method of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.SELECTED DRAWING: Figure 4

抗TL1A抗体及其制备方法和应用

Absstract of: CN119390843A

本申请公开了生物医药技术领域的一种抗TL1A抗体及其制备方法和应用。其包括重链可变区和轻链可变区，其中，所述重链可变区包含氨基酸序列如SEQ ID NO:7~9所示的HCDR1、HCDR2和HCDR3；所述轻链可变区包含氨基酸序列如SEQ ID NO:10~12所示的LCDR1、LCDR2和LCDR3。该抗TL1A抗体的生物活性表征更优，且表位与传统抗TL1A抗体不同。

一种用于炎症性肠病诊断的粪便生物标志物及其应用

Absstract of: CN119395122A

本发明公开了一种用于炎症性肠病诊断的粪便生物标志物及其应用，该粪便生物标志物为肾上腺酸。本发明通过实验首次发现了肾上腺酸在IBD患者粪便样本中呈现上调，经检测发现肾上腺酸在IBD患者粪便标本中表达上调；进一步通过ROC曲线分析肾上腺酸相比于其他钙粘蛋白等炎症活动指标而言，具有较好的诊断敏感度和特异性。本发明为IBD的临床诊断提供了新的诊断标志物，以肾上腺酸作为IBD诊断的粪便生物标志物，用于炎症性肠病的诊断，具有检测精确度高、特异性和灵敏性高、方便快捷以及安全无创等优点，对判断IBD的活动状态、调整IBD患者的诊疗及管理等均具有重要意义。

In-vitro bionic intestinal barrier injury micro-physiological system

Nº publicación: CN119391523A 07/02/2025

Applicant:

UNIV JIANGNAN
\u6C5F\u5357\u5927\u5B66

Absstract of: CN119391523A

The invention discloses an in-vitro bionic intestinal barrier injury micro-physiological system. The device comprises a stomach digestion simulation system, a small intestine digestion simulation system, a small intestine interaction simulation system, a large intestine glycolysis simulation system and a large intestine interaction simulation system. According to the invention, the physicochemical environment for digestion of patients with inflammatory bowel diseases (IBD) is simulated by adjusting parameters such as pH, and the physiological system of the patients with IBD is simulated through human-derived organs and microorganisms. The in-vitro substitution model not only simulates gastrointestinal digestion, absorption and glycolysis processes of a patient with intestinal barrier injury in vitro, but also simulates interaction between food and metabolites thereof and intestinal tracts through introduction of organoids. The model can be used for exploring the metabolic process or toxic effect of food in the body of a patient suffering from intestinal barrier injury, evaluating the bioaccessibility, metabolic fate, interaction with microorganisms and influence on intestinal physiology of the food, and realizing precise risk assessment.